Current applications of chromatographic methods for diagnosis and identification of potential biomarkers in cancer

TrAC - Trends in Analytical Chemistry

Volumn 56, Issue , 2014, Pages 1-12

  Kałuzna Czaplińska, Joanna ^a   Jóźwik, Jagoda ^a  

^a LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Biomarker; Cancer; Chromatography; Gas chromatography; GC MS; High performance liquid chromatography; HPLC; LC MS; Liquid chromatography; Mass spectrometry

Indexed keywords

BIOMARKERS; CHROMATOGRAPHIC ANALYSIS; CHROMATOGRAPHY; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC PRODUCTS; DISEASES; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

CANCER; CHROMATOGRAPHIC METHODS; COUPLED TECHNIQUES; GC-MS; HPLC; LC-MS; METABOLIC PROFILING; TREATMENT PROCESS;

DIAGNOSIS;

BIOLOGICAL MARKER;

ACCURACY; BLADDER CANCER; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CELL METABOLISM; COLORECTAL CANCER; DISEASE PREDISPOSITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CARCINOMA; LIPID PEROXIDATION; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MASS FRAGMENTOGRAPHY; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STOMACH CANCER;

EID: 84896265453     PISSN: 01659936     EISSN: 18793142     Source Type: Journal    
DOI: 10.1016/j.trac.2013.12.007     Document Type: Review

References (98)

1. Pavlou M.P., Diamandis E.P. The cancer cell secretome: a good source for discovering biomarkers?. J. Proteomics 2010, 73:1896-1906.
2. Cho W.C. Contribution of oncoproteomics to cancer biomarker discovery. Mol. Cancer 2007, 6:25.
3. Kouremenos K.A., Johansson M., Marriott P.J. Advances in gas chromatographic methods for the identification of biomarkers in cancer. J. Cancer 2012, 3:404-420.
4. Evenson M.A., Carmack G.D. Clinical chemistry. Anal. Chem. 1979, 51:35-79.
5. Hunnewell M.G., Forbes N.S. Active and inactive metabolic pathways in tumor spheroids: determination by GC-MS. Biotechnol. Prog. 2010, 26:789-796.
6. Jellum E., Stokke O., Eldjarn L. Application of gas chromatography, mass spectrometry, and computer methods in clinical biochemistry. Anal. Chem. 1973, 46:1099-1106.
7. Kałuzna-Czaplińska J. Current medical research with the application of coupled techniques with mass spectrometry. Med. Sci. Monit. 2011, 17:117-123.
8. Gooding K.M., Regnier F.E. HPLC of Biological Macromolecules Revised and Expanded 2002, CRC Press, New York. second ed.
9. Plumb R., Castro-Perez J., Granger J., Beattie I., Joncour K., Wright A. Ultra-performance liquid chromatography coupled to quadrupole-orthogonal time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2004, 18:2331-2337.
10. Kałuzna-Czaplińska J., Socha E., Rynkowski J. Determination of homovanillic acid and vanillylmandelic acid in urine of autistic children by gas chromatography/mass spectrometry. Med. Sci. Monit. 2010, 16:445-450.
11. Kałuzna-Czaplińska J. Current applications of gas chromatography/mass spectrometry in the study of organic acids in urine. Crit. Rev. Anal. Chem. 2011, 41:114-123.
12. Masson P. Quality control techniques for routine analysis with liquid chromatography in laboratories. J. Chromatogr. A 2007, 1158:168-173.
13. Biomarkers Definition Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95.
14. Strimbu K., Tavel J.A. What are biomarkers?. Curr. Opin. HIV AIDS 2010, 5:463-466.
15. WHO International Programme on Chemical Safety Biomarkers and Risk Assessment: Concepts and Principles. 1993. Retrieved from <>. http://www.inchem.org/documents/ehc/ehc/ehc155.htm.
16. Schrattenholz A., Groebe K. What does it need to be a biomarker? Relationships between resolution, differential quantification and statistical validation of protein surrogate biomarkers. Electrophoresis 2007, 28:1970-1979.
17. European Commission, Omics in personalized medicine, Summary Report, Brussels, 2010.
18. Rutkiewicz I., Namieśnik J. Skład moczu jako źródło informacji o narazeniu zawodowym na zwia{ogonek}zki organiczne. Ecol. Chem. Eng. S 2008, 15:561-585.
19. Griffin J.L., Bollard M.E. Metabonomics: its potential as a tool in toxicology for safety assessment and data integration. Curr. Drug Metab. 2004, 5:389-398.
20. Vinayavekhin N., Homan E.A., Saghatelian A. Exploring disease through metabolomics. ACS Chem. Biol. 2010, 5:91-103.
21. WHO Human genetic program. Retrieved from <>. http://www.who.int/genomics/geneticsVSgenomics/en/index.html.
22. Vincenti D.C., Murray G.I. The proteomics of formalin-fixed wax-embedded tissue. Clin. Biochem. 2013, 46:546-551.
23. Rudnicka J., Kowalkowski T., Ligor T., Buszewski B. Determination of volatile organic compounds as biomarkers of lung cancer by SPME-GC-TOF-MS and chemometrics. J. Chromatogr. B 2011, 879:3360-3366.
24. Narkowicz S., Płotka J., Polkowska Z., Biziuk M., Namieśnik J. Prenatal exposure to substance of abuse: a worldwide problem. Environ. Int. 2013, 54:141-163.
25. Amann A., Corradi M., Mazzone P., Mutti A. Lung cancer biomarkers in exhaled breath. Epert. Rev. Mol. Diagn. 2011, 11:207-217.
26. Amorim L.C., Cardeal Z. Breath air analysis and its use as a biomarker in biological monitoring of occupational and environmental exposure to chemical agents. J. Chromatogr. B 2007, 853:1-9.
27. Santos F.J., Galceran M.T. Modern developments in gas chromatography-mass spectrometry-based environmental analysis. J. Chromatogr. A. 2003, 1000:125-151.
28. Bajtarevic A., Ager C., Pienz M., Klieber M., Schwarz K., Ligor M., Ligor T., Filipiak W., Denz H., Fiegl M., Hilbe W., Weiss W., Lukas P., Jamnig H., Hackl M., Haidenberger A., Buszewski B., Miekisch W., Schubert J., Amann A. Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer 2009, 9:348.
29. Sponring A., Filipiak W., Mikoviny T., Ager C., Schubert J., Miekisch W., Amann A., Troppmair J. Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro. Anticancer Res. 2009, 29:419-426.
30. Poli D., Goldoni M., Corradi M., Acampa O., Carbognani P., Internullo E., Casalini A., Mutti A. Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber-derivatization SPME-GC/MS. J. Chromatogr. B 2010, 878:2643-2651.
31. Peng G., Tisch U., Adams O., Hakim M., Shehada N., Broza Y., Billan S., Abdah-Bortnyak R., Kuten A., Haick H. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat. Nanotechnol. 2009, 4:669-673.
32. Zeng X., Hood B., Zhao T., Conrads T., Sun M., Gopalakrishnan V., Grover H., Day R., Weissfeld J., Wilson D., Siegfried J., Bigbee W. Lung cancer serum biomarker discovery using label free LC-MS/MS. J. Thorac. Oncol. 2011, 6:725-734.
33. Cobanoglu U., Demir H., Cebi A., Sayir F., Alp H., Akan Z., Gur T., Bakan E. Lipid peroxidation, DNA Damage and coenzyme Q10 in lung cancer patients-markers for risk assessment?. Asian Pac. J. Cancer Prev. 2011, 12:1399-1403.
34. Bonakdar R.A., Guarneri E. Coenzyme Q10. Am. Fam. Physician 2005, 72:1065-1070.
35. Salgado H., de Menezes M., Storti M.P. Determination of flutamide in tablets by high-performance liquid chromatography. Acta Farm Bonaerense 2005, 24:246-249.
36. Adel M.S., Geneidi A.S., Ali Shoukri R., Saad I. In vitro evaluation of flutamide-carrier systems. Part 1: preparation and evaluation of flutamide systems with polyvinyl pyrrolidone and polyethylene glycol 4000 and 6000. Pharmazie 1997, 52:373-375.
37. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., Laxman B., Mehra R., Lonigro R.J., Li Y., Nyati M.K., Ahsan A., Kalyana-Sundaram S., Han B., Cao X., Byun J., Omenn G.S., Ghosh D., Pennathur S., Alexander D.C., Berger A., Shuster J.R., Wei J.T., Varambally S., Beecher C., Chinnaiyan A.M. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
38. Trock B.J. Application of metabolomics to prostate cancer. Urol. Oncol. Semin. Original Invest. 2011, 29:572-581.
39. Struys E.A., Heijboer A.C., van Moorselaar J., Jakobs C., Blankenstein M.A. Serum sarcosine is not a marker for prostate cancer. Ann. Clin. Biochem. 2010, 47:282.
40. Cernei N., Zitka O., Ryvolova M., Adam V., Masarik M., Hubalek J., Kizek R. Spectrometric and electrochemical analysis of sarcosine as a potential prostate carcinoma marker. Int. J. Electrochem. Sci. 2012, 7:4286-4301.
41. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., Laxman B., Mehra R., Lonigro R.J., Li Y., Nyati M.K., Ahsan A., Kalyana-Sundaram S., Han B., Cao X., Byun J., Omenn G.S., Ghosh D., Pennathur S., Alexander D.C., Berger A., Shuster J.R., Wei J.T., Varambally S., Beecher C., Chinnaiyan A.M. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
42. Whitehead T.L., Kieber-Emmons T. Applying in vitro NMR spectroscopy and 1H NMR metabonomics to breast cancer characterization and detection. Prog. Nucl. Reson. Spectrosc. 2005, 47:165-174.
43. Maruvada P., Wang W., Wagner P.D., Srivastava S. Biomarkers in molecular medicine: cancer detection and diagnosis. Biotech. Suppl. 2005, 9-15.
44. Ali I., Al-Othman Z.A., Saleem K., Hussain A., Hussain I. Role of chromatography for monitoring of breast cancer biomarkers. Recent Patentes Biomarkers 2011, 1:89-97.
45. Woo H.M., Kim K.M., Choi M.H., Jung B.H., Lee J., Kong G., Nam S.J., Kim S., Bai S.W., Chung B.C. Mass spectrometry based metabolomics approaches in urinary biomarker study of women's cancer. Clin. Chim. Acta 2009, 400:63-69.
46. Djuric Z., Heilbrun L.K., Lababidi S., Berzinkas E., Simon M.S., Kosir M.A. Levels of 5-hydroxymethyl-2'-deoxyuridine in DNA from blood of women scheduled for breast biopsy. Cancer Epidemiol. Biomarkers Prev. 2001, 10:147-149.
47. Yamazaki H., Inoue T., Koizumi M., Tanaka E., Yoshioka Y., Nakamura H., Shuo X., Inoue T. Urinary 8-hydroxy-2'-deoxyguanosine excretion as a biomarker for estimating DNA oxidation in patients undergoing external radiotherapy and/or brachytherapy. Oncol. Rep. 2005, 13:847-851.
48. Asiago V.M., Alvarado L.Z., Shanaiah N., Gowda G.A.N., Owusu-Sarfo K., Ballas R.A., Raftery D. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010, 70:8309-8318.
49. Lv W., Yang T. Identification of possible biomarkers for breast cancer from free fatty acid profiles determined by GC-MS and multivariate statistical analysis. Clin. Biochem. 2012, 45:127-133.
50. Pawlik T.M., Hawke D.H., Liu Y., Krishnamurthy S., Fritsche H., Hunt K.K., Kuerer H. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer 2006, 6:68.
51. Imai K., Ichibangase T., Saitoh R., Hoshikawa Y.A. A proteomics study on human breast cancer cell line by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry. Biomed. Chromatogr. 2008, 22:1304-1314.
52. Ichibangase T., Sugawra Y., Yamabe A., Koshiyama A., Yoshimura A., Enomoto T., Imai K. An FD-LC-MS/MS proteomic strategy for revealing cellular protein networks: a conditional superoxide dismutase 1 knockout cells. PLoS One 2012, 7:e45483.
53. Pope M.E., Soste M.V., Eyford B.A., Anderson N.L., Pearson T.W. Anti-peptide antibody screening: selection of high affinity monoclonal reagents by a refined surface plasmon resonance technique. J. Immunol. Methods 2009, 341:86-96.
54. Schoenherr M.R., Kelly-Spratt K.S., Lin C.W., Whiteaker J.R., Liu T., Holzman T., Coleman I., Feng L., Lorentzen T.D., Krasnoselsky A.L., Wang P., Liu Y. Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer. Proteomics 2011, 5:3-4.
55. Whiteaker J.R., Zhao L., Anderson L., Paulovich A.G. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol. Cell. Proteomics 2010, 9:184-196.
56. Whiteaker J.R., Lin C., Kennedy J., Hou L., Trute M., Sokal I., Yan P., Schoenherr R.M., Zhao L., Voytocich U.J., Kelly-Spratt K.S., Krasnoselsk A. A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat. Biotechnol. 2011, 29:625-634.
57. Anderson N.L., Anderson N.G., Haines L.R., Hardie D.B., Olafson R.W., Pearson T.W. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J. Proteome. Res. 2004, 3:235-239.
58. Jeffrey R., Paulovich A.G. Peptide immunoaffinity enrichment coupled with mass spectrometry for peptide and protein quantification. Clin. Lab. Med. 2011, 31:385-396.
59. Qiu Y., Cai G., Su M., Chen T., Zheng X., Xu Y., Ni Y., Zhao A., Xu L.X., Cai S., Jia W. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J. Proteome. 2009, 8:4844-4850.
60. Denkert C., Budczies J., Weichert W., Wohlgemuth G., Scholz M., Kind T., Niesporek S., Noske A., Buckendahl A., Dietel M., Fiehn O. Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol. Cancer 2008, 7:72.
61. Mal M., Koh P.K., Cheah P.Y., Chan E. Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry. Anal. Bioanal. Chem. 2012, 403:483-493.
62. Balog C.I., Stavenhagen K., Fung W.J., Koeleman C.A., McDonnell L.A., Verhoeven A., Mesker W.E., Tollenaar R.A., Deelder A.M., Wuhrer M. N-glycosylation of colorectal cancer tissues: a liquid chromatography and mass spectrometry-based investigation. Mol. Cell. Proteomics 2012, 11:571-585.
63. Ma Y.L., Qin H.L., Liu W.J., Peng J.Y., Huang L., Zhao X.P., Cheng Y.Y. Ultra-high performance liquid chromatography-mass spectrometry for metabolite analysis of urine in colorectal cancer. Dig. Dis. Sci. 2009, 54:2655-2662.
64. Teh S.K., Zheng W., Ho K.Y., Teh M., Yeoh K.G., Huang Z. Diagnosis of gastric cancer using near-infrared Raman spectroscopy and classification and regression tree techniques. J. Biomed. Opt. 2008, 13:034013.
65. Shin C.M., Kim N., Yang H.J., Cho S.I., Lee H.S., Kim J.S., Jung H.C., Song I.S. Stomach cancer risk in gastric cancer relatives: interaction between Helicobacter pylori infection and family history of gastric cancer for the risk of stomach cancer. J. Clin. Gastroenterol. 2010, 44:34-39.
66. Hu J.D., Tang H.Q., Zhang Q., Fan J., Hong J., Gu J.Z., Chen J.L. Prediction of gastric acid cancer metastasis through urinary metabolomics investigation using GC/MS. World J. Gastroenterol. 2011, 17:727-734.
67. Chen J.L., Tang H.Q., Hu J.D., Fan J., Hong J., Gu J.Z. Metabolomics of gastric cancer metastasis detected by gas chromatography and mass spectrometry. World J. Gastroenterol. 2010, 16:5874-5880.
68. Wu H., Xue R., Tang Z., Deng C., Liu T., Zeng H., Sun Y., Shen X. Metabolomic investigation of gastric cancer tissue using gas chromatography/mass spectrometry. Anal. Bioanal. Chem. 2010, 396:1385-1395.
69. Song H., Peng J.S., Dong-Sheng Y., Yang Z.L., Liu H.L., Zeng Y.K., Shi X.P., Lu B.Y. Serum metabolomics porfiling of human gastric cancer based in gas chromatography/mass spectrometry. Braz. J. Med. Biol. Res. 2012, 45:78-85.
70. Guo T., Lee S.S., Ng W.H., Zhu Y., Gan C.S., Zhu J., Wang H., Huang S., Sze S.K., Kon O.L. Global molecular dysfunctions in gastric cancer revealed by an intergrated analysis of the phosphoproteome and transcriptome. Cell. Mol. Life Sci. 2011, 68:1983-2002.
71. Gupta S., Bent S., Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann. Int. Med. 2003, 139:46-50.
72. 1H NMR and pattern recognition. Evid Based Complement. Altern. Med. 2012, 2012:843048.
73. Dunn W.B., Bailey N.J., Johnson H.E. Measuring the matabolome: current analytical technologies. Analyst 2005, 130:606-625.
74. Wu H., Xue R., Dong L., Liu T., Deng C., Zeng H., Shen X. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal. Chim. Acta 2009, 648:98-104.
75. Chen T., Xie G., Wang X., Fan J., Qiu Y., Zheng X., Qi X., Cao Y., Su M., Wang X., Xu L.X., Yen Y., Liu P., Jia W. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol. Cell. Proteomics 2011, 10. M110.004945.
76. Patterson A.D., Maurhofer O., Beyoglu D., Lanz C., Krausz K.W., Pabst T., Gonzalez F.J., Dufour J.F., Idle J.R. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res. 2011, 71:6590-6600.
77. Chen F., Xue J., Zhou L., Wu S., Chen Z. Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method. Anal. Bioanal. Chem. 2011, 401:1899-1904.
78. Wang C.Y., Chiang H.K., Chen C.T., Chiang C.P., Kuo Y.S., Chow S.N. Diagnosis of oral cancer by light-induces autofluorescence spectroscopy using double extraction wavelengths. Oral Oncol. 1999, 35:144-150.
79. Patel J.B., Shukla S.N., Patel H., Kothari K.K., Shah P.M., Patel P.S. Utility of urinary biomarkers in oral cancer. Asian Pac. J. Cancer Prev. 2007, 8:229-235.
80. Xie G.X., Chen T.L., Qiu Y.P., Shi P., Zheng X.J., Su M.M., Zhao A.H., Zhou Z.T., Jia W. Urine metabolite profiling offers potential early diagnosis of oral cancer. Metabolomics 2012, 8:220-231.
81. 1H NMR-based metabolomics. Neoplasia 2009, 11:269-276.
82. Karemore G., Sujatha, Rai L., Pai K.M., Kartha V.B., Santhosh C. Serum protein profile study of clinical samples using high performance liquid chromatography-laser induced fluorescence: case of cervical and oral cancers. Proc. SPIE 7182, Imaging Manipulation Anal. Biomol. Cells Tissues VII 2009, pp. 71820J-1-71820J-9.
83. Venkatakrishna K., Kartha V.B., Pai K.M., Krishna C.M., Ravikiran O., Kurian J., Alexander M., Ullas G. HPLC-LIF for early detection of oral cancer. Curr. Sci. 2003, 84:551-557.
84. Wei J., Xie G., Zhou Z., Shi P., Qiu Y., Zheng X., Chen T., Su M., Zhao A., Jia W. Salivary metabolite signatures of oral cancer and leukoplakia. Int. J. Cancer 2011, 129:2207-2217.
85. Hu S., Yu T., Xie Y., Yang Y., Li Y., Zhou X., Tsung S., Loo R.R., Loo J.R., Wong D.T. Discovery of oral fluid biomarkers for human oral cancer by mass spectrometry. Cancer Genomics Proteomics 2007, 4:55-64.
86. Reddy I., Sherlin H.J., Ramani P., Premkumar P., Natesan A., Chandrasekar T. Amino acid profilea of saliva from patients with oral squamous cell carcinoma using high performance liquid chromatography. J. Oral. Sci. 2012, 54:279-283.
87. Sugimoto M., Wong D.T., Hirayama A., Soga T., Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 2010, 6:78-95.
88. 1H NMR spectroscopy: a pilot study. Proc. Intl. Soc. Mag. Reson. Med. 2009, 17.
89. Smith S.D., Wheeler M.A., Plescia J., Colberg J.W., Weiss R.M., Altieri D.C. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001, 285:324-328.
90. Cicchi R., Crisci A., Nesi G., Cosci A., Giancane S., Carini M., Pavone F.S. Multispectral multiphoton lifetime analysis of human bladder tissue. Photonic Ther. Diagn. 2009, 7161. 716116-1.
91. Willis C.M., Church S.M., Guest C.M., Cook W.A., McCarthy N., Bransbury A.J., Church M.R., Church J.C. Olfactory detection of human bladder cancer by dogs: proof of principle study. BMJ 2004, 329:712.
92. Issaq H.J., Nativ O., Waybright T., Luke B., Veenstra T.D., Issaq E., Kravstov A., Mullerad M. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J. Urol. 2008, 179:2422-2426.
93. Pasikanti K.K., Esuvaranathan K., Ho P.C., Mahendran R., Kamaraj R., Wu Q.H., Chiong E., Chan E.C. Noninvasive urinary metabonomic diagnosis of human bladder cancer. J. Proteome Res. 2010, 9:2988-2995.
94. Huang Z., Lin L., Gao Y., Chen Y., Yan Z., Xing J., Hang W. Bladder cancer determination via two urinary metabolites: a biomarker pattern approach. Mol. Cell. Proteomics 2011, 10. M111.007922.
95. Weiss R.H., Lin P.Y. Kidney cancer: identification of novel targets for therapy. Kidney Int. 2006, 69:224-232.
96. Perroud B., Lee J., Valkova N., Dhirapong A., Lin P.Y., Fiehn O., Kültz D., Weiss R.H. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol. Cancer 2006, 5:64.
97. Kind T., Tolstikov V., Fiehn O., Weiss R.H. A comprehensive urinary metabolomics approach for identifying kidney cancer. Anal. Biochem. 2007, 363:185-195.
98. Kim K., Aronov P., Zakharkin S.O., Anderson D., Perroud B., Thompson I.M., Weiss R.H. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol. Cell. Proteomics 2009, 8:558-570.